肝细胞癌血清标志物的简要综述。
A concise review of serum markers for hepatocellular cancer.
作者信息
Wright Lorinda M, Kreikemeier Jeff T, Fimmel Claus J
机构信息
Division of Gastroenterology, Hepatology and Nutrition, Loyola University, Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
出版信息
Cancer Detect Prev. 2007;31(1):35-44. doi: 10.1016/j.cdp.2006.11.003. Epub 2007 Feb 12.
BACKGROUND
The rising incidence of hepatocellular cancer in the US and worldwide has sparked a renewed interest in HCC serum markers. HCC typically develops in patients with chronic liver disease and cirrhosis. It is in these target populations that serum markers are most urgently needed. Unfortunately, the currently available markers lack sensitivity and specificity. A number of novel candidate markers have recently been introduced.
METHODS
We performed a review of the literature (2001-2006) of traditional and novel serum markers for hepatocellular cancer.
RESULTS
Several promising new HCC markers have been identified over the past 5 years. They include single proteins, complex proteomics features, and tumor-specific autoantibodies. The excitement about the new markers is tempered by the realization that none of them have yet met the most stringent criteria defined by the Early Detection Research Network (EDRN).
CONCLUSION
A new generation of HCC serum markers awaits validation in properly controlled clinical studies.
背景
美国及全球肝细胞癌发病率的上升引发了对肝癌血清标志物的新关注。肝细胞癌通常在慢性肝病和肝硬化患者中发生。正是在这些目标人群中，血清标志物最为急需。不幸的是，目前可用的标志物缺乏敏感性和特异性。最近引入了一些新的候选标志物。
方法
我们对2001年至2006年有关肝细胞癌传统和新型血清标志物的文献进行了综述。
结果
在过去5年中已鉴定出几种有前景的新肝癌标志物。它们包括单一蛋白质、复杂的蛋白质组学特征和肿瘤特异性自身抗体。然而，由于意识到这些标志物均未达到早期检测研究网络（EDRN）定义的最严格标准，对新标志物的兴奋之情有所缓和。
结论
新一代肝癌血清标志物有待在适当对照的临床研究中进行验证。
Zotero 插件